Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)

被引：15
|
作者：
Efstathiou, Eleni
Titus, Mark Anton
Wen, Sijin
SanMiguel, Aileen
Hoang, Anh
De Haas-Amatsaleh, Angela
Perabo, Frank
De Phung
Troncoso, Patricia
Ouatas, Taoufik
Logothetis, Christopher
机构：
[1] Univ Athens, Dept Clin Therapeut, Dept Oncol, Alexandra Gen Hosp Athens,Med Sch, Athens, Greece
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA
[4] Astellas Global Dev, Northbrook, IL USA
[5] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[6] Astellas Pharma Global Dev Inc, Leiderdorp, Netherlands
[7] Astellas Pharma Global Dev, Leiden, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5000
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, E.
    Titus, M.
    Wen, A. S.
    San Miguel, A.
    Hoang, A.
    De Haas-Amatsaleh, A.
    Perabo, F.
    Phung, D.
    Troncoso, P.
    Logothetis, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S680 - S681
  • [2] Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC) in the era of enzalutamide (ENZA) and abiraterone acetate (AA).
    Body, Amy
    Pranavan, Gane
    Malik, Laeeq
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [4] Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration -resistant prostate cancer (mCRPC).
    Parimi, Sunil
    Eigl, Bernhard J.
    Sunderland, Katherine
    Zulficiar, Muhammad
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Seto, Leanne Chung-Yon
    Azad, Arun
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Effect of IL-6 and related mediators on resistance to abiraterone acetate (abi) and enzalutamide (enza) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Adashek, Jacob J.
    Won, Haejung
    Moreira, Dayson
    Duttagupta, Priyanka
    Twardowski, Przemyslaw
    Jones, Jeremy
    Kortylewski, Marcin
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Gaps in treatment amongst metastatic castration resistant prostate cancer (mCRPC) patients taking abiraterone acetate or enzalutamide.
    Behl, Ajay
    Ellis, Lorie
    Pilon, Dominic
    Xiao, Yongling
    Lefebvre, Patrick
    Dawson, Nancy Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Ileana, Ecaterina
    Antoun, Sami
    Albiges, Laurence
    Massard, Christophe
    Di Palma, Mario
    Escudier, Bernard J.
    Fizazi, Karim
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Indicators of clinical response to abiraterone acetate (AA) men with metastatic castration-resistant-prostate-cancer (mCRPC).
    Boegemann, Martin
    Mikah, Phillip
    Eminaga, Okyaz
    Herrmann, Edwin
    Papavassills, Philipp Marius
    Semjonow, Axel
    Krabbe, Laura-Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa Maria
    Bassi, Sunakshi
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [10] Serial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza)
    Dizman, N.
    Patel, J.
    He, M.
    Foulk, B.
    Smirnov, D. A.
    Hsu, J.
    Twardowski, P.
    Kortylewski, M.
    Bhargava, V.
    Jones, J.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2017, 28
12345